Pathos AI Secures $365 Million in Series D Funding to Advance AI-Powered Oncology Drug Development

AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE

AI-powered drug development startup Pathos AI closes $365M investment Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in Series D funding. The company didn't disclose the investors in the round. According to FierceBiotech, the raise included the participation of both new and existing Pathos backers. The company, which is now worth $1.6 billion, previously raised funding from NEA, General Atlantic and other institutional investors. Pathos has developed a platform called PathOS that promises to ease the work of pharmaceutical scientists. According to Pathos, the software hosts petabytes of oncology and genomic data. Researchers can analyze that data to identify ways of improving clinical trials for new drugs. Pathos is currently running trials for two cancer drugs licensed from Novo Nordisk AS and Prelude Therapeutics Inc. The company will use its newly raised funding round to finance its clinical studies. Additionally, part of the capital will go towards developing what Pathos describes as the largest AI foundation model for oncology research. The company's AI model is designed to process multimodal clinical, molecular and imaging data. Similarly to PathOS, it promises to help drug makers design more effective clinical trials. Pathos says that the algorithm will also simplify a number of other tasks. Many oncology research initiatives focus on cancer biomarkers, which are materials and biological processes associated with cancer. Oncologists analyze them to diagnose cancer and measure treatment effectiveness. Additionally, pharmaceutical companies often study biomarkers during the drug development process. Pathos says that its AI model will enable researchers to discover new biomarkers more efficiently. In April, the company partnered with AstraZeneca plc and healthcare technology company Tempus AI Inc. to support its AI development efforts. Tempus, which went public last year in a $410 million offering, will supply anonymized oncology data to help train the model. Pathos stated that the collaboration includes $200 million worth of data licensing and model development agreements. "Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI," said Pathos AI Chief Executive Officer Iker Huerga. "With this financing, we're building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most." Other companies are also developing AI models optimized for medical research. In March, Google LLC released TxGemma, a series of language models designed to help researchers more quickly develop new drugs. Earlier, Microsoft Corp. introduced an algorithm called TamGen that automates some of the work involved in discovering molecules with therapeutic applications.

Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company's clinical-stage pipeline and continued investment in its proprietary AI Foundation Model purpose-built for oncology. As part of this next phase, Pathos is developing the largest multimodal foundation model in oncology. This groundbreaking effort leverages deep clinical, molecular, and imaging data to improve clinical asset selection, clinical trial design, biomarker discovery, and therapeutic innovation across the oncology landscape. "Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI," said Iker Huerga, CEO of Pathos AI. "With this financing, we're building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most." Founded to accelerate innovation in oncology, Pathos is pioneering a new model for AI-enabled drug development. One that leverages multimodal data, advanced Artificial Intelligence, and deep clinical insight to bring new therapies to patients faster. With a strong focus on Artificial Intelligence, clinical development, and clinical execution, Pathos is committed to improving patient outcomes by accelerating the path from molecule to medicine. Contacts Business Development: bd@pathos.com Press Inquiries: press@pathos.com Market News and Data brought to you by Benzinga APIs